Inventor
PEI GAN
Inventor
US
Overview
Patents· 5 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations33%
C07DHeterocyclic compounds33%
A61KPreparations for medical, dental or toiletry purposes27%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium7%
PatentTitleYear
12,441,727Tricyclic compounds as inhibitors of KRAS202512,421,254KRAS modulators and uses thereof202511,999,740Fused pyrazine derivatives as A2A / A2B inhibitors202411,999,752Vinyl imidazole compounds as inhibitors of KRAS202411,673,894Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors2023Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2023–2025Patents assigned to INCYTE CORP (4)· patent assignee history
2023–2025Based in US· patent location history
2025Patents assigned to QUANTA THERAPEUTICS INC (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| INCYTE CORP | 4 | 2023–2025 |
| QUANTA THERAPEUTICS INC | 1 | 2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 5 | 2023–2025 |